

Emicizumab

Care Team Contact Information: _____

Pharmacy Contact Information: _____

Diagnosis: _____

- This treatment is used to prevent or reduce the frequency of bleeding episodes in people with hemophilia A.
 - Hemophilia A is a bleeding condition. People with it are missing or have a faulty blood clotting factor (factor VIII) that prevents their blood from clotting normally.
- It may also be used for other reasons.

Goal of Treatment: _____

- Treatment may continue for a certain time period, until it no longer works, or until side effects are no longer controlled.

Treatment Regimen

Treatment Name	How the Treatment Works	How the Treatment is Given
Emicizumab (em-i-SIZ-ue-mab): Hemlibra (hem-LEE-bruh)	Acts like a bridge to bring two blood-clotting proteins together, which allows your blood to clot normally. It mimics the job that the missing or low Factor VIII protein usually does.	Injection under the skin (subcutaneous injection) into the stomach area (abdomen), upper outer arm, or thigh.

Treatment Administration and Schedule

Treatment is typically divided into 2 phases: initial treatment and maintenance treatment.

Initial Treatment

- Emicizumab is given 1 time a week for the first 4 weeks.

Treatment Name	Initial Treatment							
	Day 1	...	Day 8	...	Day 15	...	Day 22	...
Emicizumab	✓		✓		✓		✓	

Option #1: Maintenance Treatment: Every Week

Treatment Name	Maintenance: Every Week							Next Dose
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 1
Emicizumab	✓							✓

Option #2: Maintenance Treatment: Every 2 Weeks

Treatment Name	Maintenance: Every 2 Weeks							Next Dose
	Day 1	Day 2	Day 3	Day 4	Day 5	...	Day 14	Day 1
Emicizumab	✓							✓

Option #3: Maintenance Treatment: Every 3 Weeks

Treatment Name	Maintenance: Every 3 Weeks							Next Dose
	Day 1	Day 2	Day 3	Day 4	Day 5	...	Day 21	Day 1
Emicizumab	✓							✓

Follow these instructions below, if your care team has recommended that you or your caregiver administer emicizumab at home.

Your emicizumab dosing instructions:

- See the detailed "Instruction for Use" that comes with your emicizumab prescription for information on how to prepare and inject a dose of emicizumab, and how to properly throw away (dispose of) used needles and syringes.
- Use emicizumab exactly as prescribed by your care team.
- Ask your care team about instructions for stopping bypassing agents before starting emicizumab. Examples of bypassing agents include:
 - Activated Prothrombin Complex Concentrate (APCC), such as FEIBA
 - Recombinant Factor VIIa, such as NovoSeven RT and SEVENFACT
- Your care team should show you or your caregiver how to prepare, measure, and inject your dose of emicizumab before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by your care team.
- Your care team will prescribe your dose based on your weight. If your weight changes, tell your care team.
- If you miss a dose of emicizumab on your scheduled day, take it as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. Do not give 2 doses on the same day to make up for a missed dose.

Storage and Handling of Emicizumab

- Store emicizumab in the refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze.
- Store emicizumab in the original carton to protect the vials from light.
- Do not shake emicizumab.
- Take the vial out of the refrigerator 15 minutes before use and allow it to reach room temperature before preparing an injection.
- If needed, unopened vials of emicizumab can be stored out of the refrigerator and then returned to the refrigerator. Emicizumab should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After emicizumab is transferred from the vial to the syringe, it should be used right away.
- Throw away (dispose of) any unused emicizumab left in the vial.
- Keep emicizumab and all medicines out of the reach of children and pets.

Appointments: Appointments may include regular check-ups with your care team, treatment appointments, lab visits, and imaging tests. It's important to keep your appointments whenever you can. If you miss any appointments, call your care provider as soon as possible to reschedule your appointment.

Supportive Care to Prevent and Treat Side Effects

Description	Supportive Care Given at the Clinic or Hospital	Supportive Care Taken at Home
Supportive Care to Prevent and Treat Side Effects	<hr/> <hr/> <hr/>	<hr/> <hr/> <hr/>

Common Side Effects

Side Effect	Important Information
Headache	<p>Description: Headaches are pain in your head that can vary in intensity, frequency, and location.</p> <p>Recommendations:</p> <ul style="list-style-type: none"> • Keep a headache diary to track the frequency, duration, intensity, and triggers of your headaches. • Stay hydrated by drinking plenty of water, as dehydration can contribute to headaches. • Apply a cold or warm compress to your forehead or neck to help ease headache pain. • Get adequate sleep (7 to 8 hours per night) and establish a regular sleep schedule. • Limit caffeine intake. • Your care team may recommend medicine for headaches. <p>Talk to your care team if you have:</p> <ul style="list-style-type: none"> • Severe headache • More frequent or worsening headaches • Dizziness or feeling faint • Confusion • Changes in vision
Joint Pain	<p>Description: Joint pain is pain, stiffness, swelling, or reduced movement where two bones meet.</p> <p>Recommendations:</p> <ul style="list-style-type: none"> • Keep a pain diary: note pain levels, locations, and activities that make it better or worse. • Do gentle exercise (walking, stretching, yoga) to maintain mobility and strength. Check with your care team before starting a new activity. • Use a warm compress for stiff muscles or a cold pack to reduce swelling and numb pain—use what helps the area. • Your care team may recommend or prescribe medicines, including over-the-counter pain relievers. <p>Talk to your care team if you have:</p> <ul style="list-style-type: none"> • Pain you cannot control with usual measures • Swelling, redness, or warmth in a joint • New weakness • Trouble walking or moving

<p>Injection-Site Reactions</p>	<p>Description: An injection-site reaction is a local skin reaction where the medicine is given under the skin (subcutaneous injection). It can cause pain, redness, swelling, itching, or a lump at the injection site.</p> <p>Recommendations:</p> <ul style="list-style-type: none"> • Keep the area clean and dry. Gently wash with mild soap and water. • Apply a cool, clean compress for 10–15 minutes to reduce pain and swelling. • Avoid rubbing or massaging the site, and avoid tight clothing over the area. • Rotate injection sites if instructed by your care team. • Use over-the-counter pain relievers or topical creams only if your care team says they are safe. <p>Talk to your care team if you have:</p> <ul style="list-style-type: none"> • Increasing redness, swelling, warmth, or pain at the site • A growing lump or hard area that does not get better • Drainage of pus or fluid from the site • Heavy or prolonged bleeding or new bruising at the site • Fever or chills with the injection-site reaction
--	---

Select Rare Side Effects

Side Effect	Talk to Your Care Team if You Have Any of These Signs or Symptoms
<p>Thrombotic Microangiopathy (TMA) (Boxed Warning)</p>	<p>TMA is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs.</p> <p>Emicizumab may cause TMA when used with activated prothrombin complex concentrate (aPCC; FEIBA).</p> <p>Get medical help right away if you get any of the following signs or symptoms during treatment:</p> <ul style="list-style-type: none"> • Confusion • Weakness • Swelling of arms and legs • Yellowing of skin and eyes • Stomach (abdomen) or back pain • Nausea or vomiting • Feeling sick • Decreased urination
<p>Blood Clots or Blockage (Thrombosis) in Your Blood Vessels (Boxed Warning)</p>	<p>Blood clots may form in blood vessels in your arm, leg, lung, or head.</p> <p>Emicizumab may cause blood clots when used with activated prothrombin complex concentrate (aPCC; FEIBA).</p> <p>Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment:</p> <ul style="list-style-type: none"> • Chest pain or pressure • Swelling or pain in your arms, back, neck, or jaw • Shortness of breath • Numbness or weakness on one side of your body • Trouble talking • Headache • Vision changes

**Before starting treatment, ask your care team when to call 9-1-1 or seek emergency help.
If you experience any new, worsening, or uncontrolled side effects, contact your care team immediately.**

Intimacy, Pregnancy, and Breastfeeding

- Treatment may **change how you feel about intimacy and your body**. However, physical closeness—such as holding hands and hugging—remains safe. It is common to have questions about intimacy. If needed, talk to your care team for guidance.
- It is **not known** if emicizumab may **harm an unborn baby**.
 - If you are able to become pregnant, take a pregnancy test before starting treatment.
 - Use an effective method of birth control during treatment with emicizumab.
 - If you think you might be pregnant or if you become pregnant, tell your care team right away.
- It is **not known** if emicizumab **passes into your breast milk**. You and your care team should decide the best way to feed your baby during treatment with emicizumab.

Additional Information

- **Tell your care team about all the medicines you take.**
This includes prescriptions, over-the-counter drugs, vitamins, and herbal products. Before starting any new medicine, supplement, or vaccine, ask your care team first.
- **Emicizumab increases the potential for your blood to clot.** Carefully follow your care team’s instructions on when to use an on-demand bypassing agent or factor VIII (FVIII), and the recommended dose and schedule for breakthrough bleed treatment.
- **Emicizumab may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading.** Talk to your care team about how this may affect your care.
- **This Patient Education Sheet may not describe all possible side effects.**
Call your care team for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Notes

Updated Date: June 2, 2026

Scan the QR code below to access this education sheet.



Important notice: The Association of Cancer Care Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), Network for Collaborative Oncology Development & Advancement, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering information for and developing this patient education guide. This guide represents a brief summary of the medication derived from information provided by the drug manufacturer and other resources.

This guide does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication and should not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

Permission: Patient Education Sheets are provided as a free educational resource for patients with cancer and their caregivers in need of concise, easy to understand information about cancer therapy. Healthcare providers are permitted to copy and distribute the sheets to patients as well as direct patients to the Patient Education Sheets website. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holders. Permission requests, including direct linking from Electronic Health Records, and licensing inquiries should be emailed to patienteducation sheets@ncoda.org.

Copyright © 2026 by Network for Collaborative Oncology Development & Advancement, Inc. All rights reserved.

PES-619